Boardroom Alpha
Meeting calendar
TVGN · Annual meeting · Monday, August 24, 2026

Tevogen Inc

6 nominees · 4 ballot items.

Four proposals: elect two Class II directors; ratify KPMG LLP as independent auditors; approve an amendment to the 2024 Omnibus Incentive Plan to add 100,000,000 shares; and approve an amendment to the Certificate of Incorporation to permit stockholder action by written consent — the Board recommends FOR all proposals.

Market cap
$391M
1Y TSR
-74.6%
Board grade
D
Record date
Jul 23, 2026
Filing
DEF 14A
Meeting concluded · Aug 24, 2026

Follow how the vote landed and what changed on Tevogen Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot4

  1. 1

    Election of Class II Directors (Dr. Keow Lin Goh and Victor Sordillo

    ManagementBoard: FOR

    Elect Dr. Keow Lin Goh and Victor Sordillo as Class II directors to serve three-year terms or until their successors are elected and qualified.

  2. 2

    Ratification of Appointment of Independent Registered Public Accounting Firm (KPMG LLP

    ManagementBoard: FOR

    Ratify the Audit Committee’s appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

  3. 3

    Amendment to the 2024 Omnibus Incentive Plan to Increase Shares Available for Issuance by 100,000,000

    ManagementBoard: FOR

    Approve an amendment to Section 4.1 of the Tevogen 2024 Omnibus Incentive Plan to increase the maximum number of shares reserved for issuance under the plan by 100,000,000 shares (from 3,179,028 to 103,179,028 shares).

    More detail

    This proposal asks shareholders to approve Amendment No.2 to the Company’s 2024 Omnibus Incentive Plan to add 100,000,000 shares to the plan’s reserve, increasing the stated Initial Share Limit to 102,800,000 shares and thereby enabling substantially larger future equity awards. Management frames the request as necessary to attract, retain, motivate, and reward employees, directors, and consultants and to align long-term equity incentives with stockholder value. The requested increase is very large relative to the Company’s outstanding shares as of the record date (the filing notes the increase represents roughly 15.6 times current outstanding shares), which creates meaningful potential dilution to existing public shareholders and could materially alter ownership and voting power if a substantial portion of the new shares are granted to insiders. The plan includes some governance guardrails (e.g., no liberal share recycling, no repricing without stockholder approval, limits on SAR/option pricing, and clawback/forfeiture mechanisms), but the amendment still grants the Board broad discretion to allocate awards and to determine recipients and amounts. Given that the Company is a controlled company and the CEO, Dr. Saadi, beneficially holds a majority of voting power, the dilution risk may disproportionately benefit insiders; the proxy itself acknowledges directors and executive officers could receive a substantial portion of awards. The Board notes past usage of a prior 2,000,000-share increase and that most of those shares were consumed by grants, illustrating the potential for the new pool to be used quickly. The proposal will require a majority of shares present and entitled to vote to pass, which means large shareholders and insiders can significantly influence the outcome. For an analyst, the key tradeoffs are management’s stated need for a deep equity pool to preserve talent and execute strategy against the clear downside of substantial dilution and concentrated insider influence; careful post-approval monitoring of grant recipients, vesting schedules, and any future large awards to insiders will be critical. While the Board recommends FOR, investors should weigh the company’s hiring and retention needs, historical grant practices, and the governance implications of awarding a very large share pool under a controlled-company structure.

  4. 4

    Amendment to Certificate of Incorporation to Permit Stockholder Action by Written Consent

    ManagementBoard: FOR

    Approve an amendment to the Certificate of Incorporation to permit stockholders to take action by written consent in lieu of a meeting in accordance with Section 228 of the Delaware General Corporation Law.

    More detail

    This proposal would amend the Company’s Certificate of Incorporation to allow stockholder action by written consent under Delaware law, providing an alternative procedural mechanism to convening a special meeting. Management argues that written consent is a more efficient and flexible tool that reduces cost, delay, and execution risk and can facilitate timely corporate responses; the Board also expects to adopt bylaws that will add procedural safeguards. The proposal presents governance trade-offs: while it can streamline legitimate stockholder-driven actions and reduce administrative burden, in a controlled-company context it enables a majority holder to effect corporate actions without convening a meeting, which could reduce minority stockholder engagement and the public scrutiny that meetings sometimes ensure. The proxy explicitly notes that Dr. Saadi beneficially owns approximately 57.8% of the voting power, and the amendment would therefore be disproportionately valuable to a controlling stockholder who could deliver the requisite consents without soliciting others — a point the Board acknowledges. The Company cites statutory safeguards (DGCL notice and record-date rules), fiduciary duties of directors, federal disclosure obligations, and planned bylaw protections as protections for minority holders, but these are procedural and legal backstops rather than structural limits on a controlling holder’s practical ability to act. For investors evaluating this proposal, key considerations include the controlling shareholder dynamic, the company’s disclosure practices, whether the Board will adopt meaningful bylaw constraints, and the likelihood that written consent would be used to effect actions benefiting insiders. The Board recommends FOR, viewing the amendment as enhancing flexibility and stockholder rights in general, but minority investors should assess the balance of efficiency versus concentrated control.

Director elections

Nominees on the ballot6

Independent
Tenure on this board
2.7 yrs
Also a director at
Livanova PLC (LIVN)
Ownership

Top institutional holders10

Latest 13F quarter
1VANGUARD CAPITAL MANAGEMENT LLC0.4%23,976$136K
2MORGAN STANLEY0.3%18,083$102K
3AQR CAPITAL MANAGEMENT LLC0.3%16,953$96K
4GOLDMAN SACHS GROUP INC0.2%14,163$80K
5FMR LLC0.2%9,826$56K
6JANE STREET GROUP, LLC0.1%7,351$42K
7Russell Investments Group, Ltd.0.1%6,532$37K
8JANE STREET GROUP, LLC0.1%3,824$22K
9Tower Research Capital LLC (TRC0.0%1,494$8K
10UBS Group AG0.0%924$5K
Filings

Tevogen Inc proxy statements and SEC reports

Annual & quarterly reports (10-K, 10-Q)
Proxy statements (DEF 14A)
Reference

Frequently asked questions

When is the Tevogen Inc 2026 annual meeting?
Tevogen Inc (TVGN) holds its 2026 annual shareholder meeting on Monday, August 24, 2026.
What is the record date for the Tevogen Inc 2026 meeting?
The record date for the Tevogen Inc 2026 meeting is Thursday, July 23, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Tevogen Inc's 2026 meeting?
The board is presenting 6 director nominees at the Tevogen Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Tevogen Inc 2026 meeting?
Shareholders will vote on 4 proposals at the Tevogen Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer